Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
MNMD Stock Forecast 2026-2027
$47.07
Current Price
$4.58B
Market Cap
Buy 13
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to MNMD Price Targets
+29.6%
To High Target of $61.00
-47.9%
To Median Target of $24.50
-66.0%
To Low Target of $16.00
MNMD Price Momentum
+5.8%
1 Week Change
+90.2%
1 Month Change
+465.1%
1 Year Change
+251.5%
Year-to-Date Change
-4.3%
From 52W High of $49.20
+518.5%
From 52W Low of $7.61
📊 TOP ANALYST CALLS
Did MNMD Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Mind Medicine is one of their latest high-conviction picks.
Latest MNMD Stock Price Targets & Analyst Predictions
Based on our analysis of 15 Wall Street analysts, MNMD has a bullish consensus with a median price target of $24.50 (ranging from $16.00 to $61.00). The overall analyst rating is Strong Buy (9.5/10). Currently trading at $47.07, the median forecast implies a -47.9% downside. This outlook is supported by 13 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Justin Walsh at Jones Trading, projecting a 29.6% upside. Conversely, the most conservative target is provided by Joel Beatty at Baird, suggesting a 66.0% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MNMD Analyst Ratings
13
Buy
0
Hold
0
Sell
MNMD Price Target Range
Low
$16.00
Average
$24.50
High
$61.00
Current: $47.07
Latest MNMD Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MNMD.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 23, 2025 | Jones Trading | Justin Walsh | Buy | Initiates | $61.00 |
| Nov 7, 2025 | Canaccord Genuity | Sumant Kulkarni | Buy | Maintains | $25.00 |
| Nov 7, 2025 | RBC Capital | Brian Abrahams | Outperform | Maintains | $20.00 |
| Oct 13, 2025 | Needham | Ami Fadia | Buy | Initiates | $28.00 |
| Aug 4, 2025 | Oppenheimer | Jay Olson | Outperform | Reinstates | $25.00 |
| Aug 1, 2025 | Chardan Capital | Rudy Li | Buy | Maintains | $20.00 |
| May 9, 2025 | Chardan Capital | Rudy Li | Buy | Maintains | $20.00 |
| Mar 7, 2025 | Baird | Joel Beatty | Outperform | Maintains | $16.00 |
| Mar 7, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $55.00 |
| Jan 31, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $55.00 |
| Jan 28, 2025 | Evercore ISI Group | Gavin Clark-Gartner | Outperform | Initiates | $23.00 |
| Dec 20, 2024 | Chardan Capital | Rudy Li | Buy | Initiates | $20.00 |
| Dec 17, 2024 | Oppenheimer | Francois Brisebois | Outperform | Reiterates | $20.00 |
| Nov 11, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $55.00 |
| Sep 16, 2024 | Canaccord Genuity | Sumant Kulkarni | Buy | Maintains | $14.00 |
| Aug 29, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Maintains | $55.00 |
| Jul 31, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $35.00 |
| Jul 24, 2024 | Roth MKM | Jason Wittes | Buy | Maintains | $36.00 |
| Jun 21, 2024 | Cantor Fitzgerald | Charles Duncan | Overweight | Reiterates | $N/A |
| Jun 5, 2024 | RBC Capital | Brian Abrahams | Outperform | Reiterates | $22.00 |
Definium Therapeutics, Inc. (MNMD) Competitors
The following stocks are similar to Mind Medicine based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Definium Therapeutics, Inc. (MNMD) Financial Data
Valuation Metrics
Market Cap
$4.58B
Enterprise Value
$1.31B
P/E Ratio
N/A
PEG Ratio
-8.5x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+4.5%
Current Ratio
3.3x
Debt/Equity
31.4x
ROE
-85.6%
ROA
-33.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Definium Therapeutics, Inc. (MNMD) Business Model
About Definium Therapeutics, Inc.
What They Do
Develops psychedelic-based therapies for mental health disorders.
Business Model
Definium Therapeutics operates as a clinical-stage biopharmaceutical company that generates revenue through the development of innovative therapeutics targeting psychiatric and neurological disorders. The company focuses on creating evidence-based treatments, leveraging scientific research to advance its drug candidates through clinical trials, including its lead program DT120 for major depressive disorder and generalized anxiety disorder, which has received FDA Breakthrough Therapy Designation.
Additional Information
Based in New York City, Definium Therapeutics is advancing multiple programs, including DT402 for autism spectrum disorder, specifically addressing social communication challenges. The company positions itself in the growing field of psychedelic therapeutics, aiming to provide scalable and accessible treatment options for prevalent mental health issues.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
105
CEO
Mr. Robert Barrow
Country
United States
IPO Year
2021
Website
definiumtx.comDefinium Therapeutics, Inc. (MNMD) Latest News & Analysis
Latest News
Frequently Asked Questions About MNMD Stock
What is Definium Therapeutics, Inc.'s (MNMD) stock forecast for 2027?
Based on our analysis of 15 Wall Street analysts, Definium Therapeutics, Inc. (MNMD) has a median price target of $24.50. The highest price target is $61.00 and the lowest is $16.00.
Is MNMD stock a good investment in 2027?
According to current analyst ratings, MNMD has 13 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $47.07. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for MNMD stock?
Wall Street analysts predict MNMD stock could reach $24.50 in the next 12 months. This represents a -47.9% decrease from the current price of $47.07. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Definium Therapeutics, Inc.'s business model?
Definium Therapeutics operates as a clinical-stage biopharmaceutical company that generates revenue through the development of innovative therapeutics targeting psychiatric and neurological disorders. The company focuses on creating evidence-based treatments, leveraging scientific research to advance its drug candidates through clinical trials, including its lead program DT120 for major depressive disorder and generalized anxiety disorder, which has received FDA Breakthrough Therapy Designation.
What is the highest forecasted price for MNMD Definium Therapeutics, Inc.?
The highest price target for MNMD is $61.00 from Justin Walsh at Jones Trading, which represents a 29.6% increase from the current price of $47.07.
What is the lowest forecasted price for MNMD Definium Therapeutics, Inc.?
The lowest price target for MNMD is $16.00 from Joel Beatty at Baird, which represents a -66.0% decrease from the current price of $47.07.
What is the overall MNMD consensus from analysts for Definium Therapeutics, Inc.?
The overall analyst consensus for MNMD is bullish. Out of 15 Wall Street analysts, 13 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $24.50.
How accurate are MNMD stock price projections?
Stock price projections, including those for Definium Therapeutics, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 14, 2026 12:27 PM UTC